Explore

CVS says GLP-1s save money when priced below $350 per month

CVS says GLP-1s save money when priced below $350 per month

By Amina Niasse NEW YORK, Nov 14 (Reuters) - CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month as reduced use of medical services, such as hospitalizations and emergency room visits, lower spending enough to offset drug

University of Pittsburgh Researchers Discover Widespread Drug-Impacting Genetic Variants in All of Us Cohort

University of Pittsburgh Researchers Discover Widespread Drug-Impacting Genetic Variants in All of Us Cohort

A study led by researchers at the University of Pittsburgh, utilizing data from the National Institutes of Health’s All of Us Research Program, has revealed that every individual in a diverse sample of nearly 100,000 participants carries at least one genetic variant affecting how their body processes medications. The study, published in Science Translational Medicine, found that participants had a median of nine such variants. Furthermore, over 24% of these individuals had been prescribed a medication known to interact with a variant they carried. The research team evaluated the frequency of 16 genetic variants known to influence the effectiveness or toxicity of various medications. This discovery highlights the potential for pharmacogenomics (PGx) to improve individualized prescribing and reduce adverse drug effects. The All of Us Research Program, a large-scale initiative, aims to gather health data from one million people across the U.S. to understand how lifestyle, environment, and genes impact health ...

PharmaEssentia USA Expands Operations, Focuses on Innovative Biologics for Hematology, Oncology, and Immunology

PharmaEssentia USA Expands Operations, Focuses on Innovative Biologics for Hematology, Oncology, and Immunology

PharmaEssentia USA Expands Operations, Focuses on Innovative Biologics for Hematology, Oncology, and Immunology

Gene Therapy for Rare Diseases Dominates Approved Products and Clinical Trials

Gene Therapy for Rare Diseases Dominates Approved Products and Clinical Trials

A recent cross-sectional registry analysis has revealed that rare disorders account for 80% of approved gene therapy products and over 44% of all registered gene therapy clinical trials. The study, which analyzed 1,464 registered clinical investigations, identified 646 studies specifically targeting rare conditions, spanning 175 distinct rare diseases. The findings indicate a substantial and sustained growth in rare disease research over the past decade, with annual trial initiations more than tripling from 21 in 2015 to 73 in 2024. The research team integrated data from multiple public registries, including the United States Food and Drug Administration (FDA), Orphanet, and ClinicalTrials.gov. Of the 30 FDA-approved gene therapy products, 24 (80%) carried at least one rare disease indication, covering 16 distinct rare diseases. Despite this progress, early-phase trials still constitute nearly two-thirds of the investigational pipeline, and there is a significant geographic concentration of trials, with th...

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Fresenius and WuXi Biologics Announce Exclusive Agreement to Expand Biosimilars Pipeline

Fresenius and WuXi Biologics Announce Exclusive Agreement to Expand Biosimilars Pipeline

Fresenius and WuXi Biologics Announce Exclusive Agreement to Expand Biosimilars Pipeline

Medidata Refines Patient Burden Index to Optimize Clinical Trial Protocols

Medidata Refines Patient Burden Index to Optimize Clinical Trial Protocols

Medidata, a Dassault Systemes company, has significantly refined its Patient Burden Index (PBI), a data-driven metric designed to quantify the demands placed on participants in clinical trials. This updated index evaluates six core dimensions: pain, invasiveness, harmful exposure, duration, anxiety, and item count, across over 4,000 clinical activities. These activities include modern drug modalities such as CAR-T and gene therapy, as well as digital tools increasingly integrated into trial conduct. The PBI's refinement involved a year-long effort incorporating literature review, cross-functional clinical expertise, and direct input from trial participants. The results are now categorized into clear Low, Medium, and High burden tiers, providing protocol designers with an immediate and interpretable signal for necessary adjustments. This tool aims to help teams design protocols that participants can realistically complete, thereby identifying potential burdens early in the process.

Maven Clinic Expands In-Network Virtual Menopause Care to 80% of Commercially Insured Americans

Maven Clinic Expands In-Network Virtual Menopause Care to 80% of Commercially Insured Americans

Maven Clinic has announced that its virtual clinic for perimenopause, menopause, and hormone care is now in-network with over 475 health plans, including major providers like Aetna, UnitedHealthcare, and Blue Cross Blue Shield. This expansion makes specialized virtual menopause care accessible to approximately 80% of commercially insured individuals in the U.S. Previously, patients without an employer-sponsored Maven benefit typically paid out-of-pocket or through a consumer subscription. With this change, patients will now only be responsible for their cost share, such as copays, coinsurance, or deductibles, making specialized care more affordable. The company stated that it verifies eligibility and provides estimated costs before appointments. While many menopause-related consultations can be effectively handled via video, certain procedures like pelvic exams, Pap tests, mammograms, bone density scans, and blood draws still require in-person visits. Maven Clinic also plans to expand its covered services ...

Representative Jake Auchincloss Introduces 'Faster Clinical Trials Act' to Modernize Drug Development

Representative Jake Auchincloss Introduces 'Faster Clinical Trials Act' to Modernize Drug Development

U.S. Rep. Jake Auchincloss, D-Mass., has introduced H.R. 10857, known as the 'Faster Clinical Trials Act.' This comprehensive bill aims to accelerate medical research, enhance clinical trial efficiency, and strengthen oversight in drug development and labeling. Key provisions include establishing an FDA-led 'Cures in Care' program to facilitate routine clinical trials within standard healthcare settings, promoting decentralized methods, and prioritizing underserved populations. The bill also mandates more standardized data sharing for point-of-care trials, expands FDA and CMS guidance on trial funding, and updates oversight rules. Furthermore, it seeks to modernize the review of early-stage trials, align with international standards, and scrutinize foreign data used in FDA decisions. The legislation also proposes creating an FDA Rare Disease Innovation Hub to expedite rare disease trials and biomarker development. Additionally, it would establish an Oncology Center of Excellence and a new FDA process for r...

Senator Cassidy Aide Announces Forthcoming Legislation to Reform No Surprises Act

Senator Cassidy Aide Announces Forthcoming Legislation to Reform No Surprises Act

Senator Bill Cassidy, R-La., a key author of the No Surprises Act (NSA), is preparing to release new legislation aimed at reforming the law, according to his health policy advisor, Romney Gripado. The NSA, enacted in 2020, was designed to protect patients from unexpected medical bills. While successful in this regard, it has faced criticism from both insurers and providers. Insurers argue that providers are exploiting the law's payment resolution process to secure inflated awards, often aided by supposedly independent arbiters. Conversely, providers claim insurers are delaying or withholding payments. Cassidy's proposed bill seeks to address these issues by strengthening program integrity, improving oversight of arbiters, restoring accountability, and increasing transparency in the dispute resolution process. The legislation also aims to protect employers from unnecessary costs, ensure timely compensation for providers, and tackle incentives that may be driving increased arbitration utilization. This initi...

U.S. Employers Face Steep Health Benefit Cost Increases for 2027, Driving Cost-Cutting Measures

U.S. Employers Face Steep Health Benefit Cost Increases for 2027, Driving Cost-Cutting Measures

U.S. Employers Face Steep Health Benefit Cost Increases for 2027, Driving Cost-Cutting Measures

University of Cincinnati Hosts Summit on AI's Role in Reshaping Healthcare and Lowering Costs

University of Cincinnati Hosts Summit on AI's Role in Reshaping Healthcare and Lowering Costs

Professionals in artificial intelligence and healthcare recently convened at the University of Cincinnati for a summit focused on how AI can transform medicine, from disease diagnosis to reducing patient costs. The event addressed the rising healthcare expenses, with a national survey by Marsh McLennan indicating an 8% average increase in employer-sponsored health plan costs for the coming year, the highest since 2003. Summit organizer Jamison DeAngelis expressed optimism that AI could enhance the efficiency of healthcare systems, ultimately leading to lower patient costs. Dr. Kelly Kohen, director of the AI Biolab Digital Futures at the University of Cincinnati, highlighted AI's potential to deliver personalized treatment tailored to individual needs. Dr. Alex Tobin, a radiologist, emphasized AI's capability to meticulously analyze medical images, potentially identifying patterns that could predict optimal therapies or patient outcomes. Kyle Frye, CEO of Cortex AI, noted that AI tools could also assist in...